Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.01
Nov 20 • 3:59 PM ET Dollar change-0.04 Percentage change(-3.81%)
Aftermarket Close
0.9905
Aftermarket • 5:00 PM ET Dollar change-0.0195 Percentage change(-1.93%)
Index
RUT
Market Cap
110.69M
Enterprise Value
110.30M
Income
-19.24M
Sales
88.34M
Book/sh
0.47
Cash/sh
0.66
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
146
IPO
Apr 22, 2010
P/E
-
Forward P/E
-
PEG
-
P/S
1.25
P/B
2.16
P/C
1.52
P/FCF
-
EV/EBITDA
-
EV/Sales
1.25
Quick Ratio
2.75
Current Ratio
2.81
Debt/Eq
1.41
LT Debt/Eq
1.12
Option/Short
Yes / Yes
EPS (ttm)
-0.20
EPS next Y
-0.29
EPS next Q
-0.07
EPS this Y
26.86%
EPS next Y
20.70%
EPS next 5Y
32.32%
EPS past 3/5Y
0.62% -4.52%
Sales past 3/5Y
-20.22% 0.38%
EPS Y/Y TTM
73.74%
Sales Y/Y TTM
66.89%
EPS Q/Q
65.12%
Sales Q/Q
123.95%
Insider Own
7.11%
Insider Trans
-0.35%
Inst Own
68.88%
Inst Trans
7.40%
ROA
-14.35%
ROE
-42.85%
ROIC
-17.69%
Gross Margin
81.28%
Oper. Margin
-14.42%
Profit Margin
-21.77%
SMA20
-8.60%
SMA50
-19.38%
SMA200
-43.40%
Trades
Shs Outstand
109.52M
Shs Float
101.81M
52W High
2.98 -66.11%
52W Low
0.90 12.22%
Volatility
9.58% 8.45%
ATR (14)
0.10
RSI (14)
41.32
Beta
2.36
Rel Volume
2.27
Avg Volume
911.76K
Volume
2,067,438
Perf Week
-12.93%
Perf Month
-22.90%
Perf Quarter
-39.16%
Perf Half Y
-59.44%
Perf YTD
-38.04%
Perf Year
-35.67%
Perf 3Y
-49.25%
Perf 5Y
-97.29%
Perf 10Y
-79.80%
Prev Close
1.05
Price
1.01
Change %
-3.81%
Consensus
Buy
Avg. Price Target
$6.67
Implied Upside
+560.4%
Analysts11incl. previous ratings
Rating Distribution8 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 19, 2024Downgrade
TThe Benchmark Company
Buy → Hold
Jun 03, 2024Resumed
JEF logoJJefferies
Buy$5+395.0%
May 30, 2024Initiated
CCantor Fitzgerald
Overweight$11+989.1%
Feb 29, 2024Upgrade
TThe Benchmark Company
Hold → Buy
Nov 07, 2023Downgrade
TThe Benchmark Company
Buy → Hold
Aug 07, 2023Downgrade
TD logoTTD Cowen
Outperform → Market Perform$21 → $4+296.0%
May 09, 2023Downgrade
HH.C. Wainwright
Buy → Neutral
Mar 31, 2022Resumed
PPiper Sandler
Overweight$35+3,365.3%
Mar 02, 2022Resumed
CCowen
Outperform
Apr 12, 2021Initiated
PPiper Sandler
Overweight$32+3,068.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOORE ALISONPresident and CEONov 16 '26Sale1.1410,65112,111233,520Nov 18 04:30 PM
MOORE ALISONOfficerNov 16 '26Proposed Sale1.1410,65112,111Nov 16 09:37 PM
De Vre RaymondDirectorNov 09 '26Sale1.111,0881,20883,723Nov 10 04:05 PM
Erbez GeorgiaSee RemarksOct 12 '26Sale1.366,3358,61960,475Oct 14 05:19 PM
MOORE ALISONPresident and CEOOct 12 '26Sale1.366,3358,619244,171Oct 14 05:17 PM
Erbez GeorgiaOfficerOct 12 '26Proposed Sale1.366,3358,619Oct 13 04:32 PM
MOORE ALISONOfficerOct 12 '26Proposed Sale1.366,3358,619Oct 13 04:27 PM
De Vre RaymondDirectorJun 11 '26Sale2.372,6056,17484,811Jun 11 08:19 PM
Lutz StefanChief Scientific OfficerFeb 24 '26Sale1.135,8626,641130,421Feb 25 07:54 PM
Lutz StefanOfficerFeb 24 '26Proposed Sale1.175,2806,178Feb 23 08:08 PM
Lutz StefanChief Scientific OfficerFeb 06 '26Sale1.312,4923,257136,283Feb 09 04:07 PM
Erbez GeorgiaSee RemarksFeb 06 '26Sale1.313,8265,00166,810Feb 09 04:07 PM
MOORE ALISONPresident and CEOFeb 06 '26Sale1.313,8265,001250,506Feb 09 04:06 PM
Norrett KevinOfficerFeb 06 '26Proposed Sale1.273,2914,180Feb 06 06:18 PM
Lutz StefanOfficerFeb 06 '26Proposed Sale1.272,4603,124Feb 06 06:15 PM
KEVIN NORRETTOfficerJan 16 '26Proposed Sale1.671,7452,914Jan 16 05:09 PM
Lutz StefanCSOJan 07 '26Sale1.704,6857,950138,775Jan 08 06:51 PM
Norrett KevinOfficerJan 07 '26Proposed Sale1.706,12310,409Jan 07 09:17 PM
Opaleye Management Inc.10% OwnerDec 01 '25Sale1.67253,533422,766179,989Dec 01 05:41 PM
Opaleye Management Inc.10% OwnerNov 28 '25Sale1.75107,490188,108188,522Dec 01 05:41 PM
Opaleye Management Inc.10% OwnerNov 26 '25Sale1.745,0008,706191,012Dec 01 05:41 PM
Codexis, Inc. is an enzyme engineering company, which engages in technology solutions to improve therapeutics manufacturing. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
PresidentDr. Alison Moore Ph.D.
CFO & Chief Business OfficerMs. Georgia L. Erbez
Chief Scientific OfficerDr. Stefan Lutz Ph.D.
Senior Vice President of Sales & MarketingMr. Britton Jimenez
Senior VP & Head of Human ResourcesMs. Karen Frechou-Armijo